BIOMARIN PHARMACEUTICAL INC. STIFEL 2026 HEALTHCARE CONFERENCE - AMICUS THERAPEUTICS INC

Explicit Guidance:

• Synergies & Expenses: $220 million in operating expense synergies from the Amicus Therapeutics acquisition expected to be fully realized on a run-rate basis in 2028; integration mostly completed by mid-2028.
• Profitability: Amicus business unit expected to achieve a ~60% operating margin by the end of the decade.
• Balance Sheet: Deleveraging target to maintain net leverage below 2.5x by mid-2028.
• 2027 Operating Plan: Preliminary confirmation that 2027 revenue guidance is being finalized; potential inclusion of Hypochondroplasia contribution from a May 30, 2027 PDUFA approval, though full clarity on label/timing remains pending.
• Tax Rate/Capex/Dividends: No explicit quantitative guidance provided for these specific line items in this transcript.

Business-Segment Outlook:

• Metabolics (Amicus Portfolio):
  • Gallifold (Fabry Disease): Patient growth of 20% in the third quarter (single-market focus).
  • Pomp/Opfolda (Pompe Disease): Revenue growth of ~60% (early growth cycle).
  • Pipeline Additions: Four new assets added this year:
    • BMN 450: First potential subcutaneous ERT for Fabry disease (mutation-agnostic); targeting patients with amenable and non-amenable mutations, including potential end-organ benefits (heart).
    • BMN 440: First potential oral substrate reduction therapy for Hypophosphatasia (HPP); targeting adults and children (excluding infants); aiming for 30–50% reduction in serum pyrophosphate (validated surrogate).
    • BMN 430: Preclinical program for Renau Syndrome.
    • BMN 820: Partnered asset for Focal Segmental Glomerulosclerosis (FSGS) via Amicus acquisition; oral CCR2 inhibitor.
• Voxogo (BMN 333):
  • Hypochondroplasia: PDUFA decision expected May 30, 2027. Addressable diagnosed population estimated at 14,000 globally (approx. 1/3 of Achondroplasia's 24,000 due to lower diagnosis rates).
  • Development Strategy: Phase 2/3 study for Hypochondroplasia/Achondroplasia designed with 30 patients (3 doses) plus 10 internal controls on current standard of care; utilizing Bayesian models to target specific probability of success.

Market and Competitive Outlook:

• Hypophosphatasia: Estimated 9,000 diagnosed patients in the U.S., with only 10–30% currently on treatment (higher penetration in infants, lower in adults).
• Fabry Disease: Current ERTs (e.g., Galifold) cover only 35–50% of the population due to mutation requirements; BMN 450 aims to capture the remaining ~50% of mutation-agnostic patients.
• Achondroplasia/Hypochondroplasia: Market expansion driven by established treatment centers and "skeletal dysplasia centers" formed during the ACON launch, which now serve as hubs for Hypo diagnosis and treatment.
• FSGS: Shift in regulatory acceptance allowing 2-year proteinuria reduction as an approvable endpoint for full FDA approval, reducing development timelines compared to historical reliance on eGFR decline.

Macro / Industry Outlook:

• Regulatory Pathways: Emphasis on "mutation-agnostic" approvals for Fabry and "oral" therapies for HPP to address unmet needs in adult populations; utilization of blood markers (Lyso-Gb3, pyrophosphate) to accelerate Phase 2 readouts and avoid invasive biopsies.
• Treatment Burden: Industry focus shifting toward patient convenience (subcutaneous vs. IV, oral vs. injectable) and reduced dosing frequency to improve adherence and outcomes.
• Diagnosis Gaps: Significant headwinds in patient identification (diagnosis rates) in Hypochondroplasia compared to Achondroplasia, though genetic testing availability is improving.

Strategic Initiatives:

• M&A Strategy: Current priority is deleveraging following the Amicus acquisition; no immediate commitment to new billion-dollar deals. Future M&A will focus on clinical-stage assets within therapeutic areas or tangential areas once leverage improves.
• Pipeline Rebuilding: Active recruitment for global Phase 2 studies; prioritizing assets with strong biology and potential for convenience (e.g., oral, subcutaneous).
• Capacity/Integration: Amicus integration largely complete by mid-2028; focus on realizing $220M in synergies to boost bottom-line growth.
• Launch Strategy: Hypochondroplasia launch anticipated in H2 2027 following May PDUFA; ramp expected to mirror other rare disease launches (second-half focus).

Risks and Headwinds to Outlook:

• Clinical/Regulatory: Uncertainty regarding Phase 2 data readouts for BMN 450, BMN 440, and BMN 333 (no specific timing dates committed for BMN 450/440; BMN 333 data expected 2027); potential for Phase 2 non-inferiority failure for BMN 333 if Bayesian probability cutoff is missed.
• Safety: Potential (though deemed unlikely by management) for hypotension with BMN 333 due to higher exposure compared to current standards, or excessive growth velocity exacerbating spinal stenosis.
• Commercial/Diagnostic: Lower diagnosis rates for Hypochondroplasia and HPP (adults) compared to current standards; need to prove efficacy in adult phenotypes for HPP where endpoints (e.g., six-minute walk test) are heterogeneous.
• Financial: Delays in realizing $220M synergies or extending the timeline beyond 2028 could impact bottom-line accretion; potential for PDUFA label restrictions to limit initial revenue contribution.

Management Tone on the Future:

• Confidence: High confidence in the biological potential of new assets (BMN 440, BMN 450, BMN 333) and the validation of surrogate markers (pyrophosphate, proteinuria).
• Cautious Optimism: Prudent approach to guidance for 2027 due to lack of full label clarity for Hypochondroplasia; management explicitly avoids over-promising on specific timing for data readouts outside of the PDUFA date.
• Strategic Discipline: Clear shift from deal-making to execution and integration, prioritizing deleveraging before re-engaging in significant M&A.

Miscellaneous:

• Q3 Performance: Revenue growth of 32% YoY, reaching $1B total revenue; Metabolics unit grew 44%.
• Amicus Integration: Two assets added (Gallifold, Pomp/Opfolda) driving double-digit growth; deal expected to be highly accretive to the bottom line.